Title : The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo.

Pub. Date : 2019 Mar 7

PMID : 30845975






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In contrast, the bortezomib/birinapant regimen upregulated TRAF3, downregulated TRAF2, and diminished p52 processing and BCL-XL expression, consistent with disruption of the non-canonical NF-kappaB pathway. birinapant TNF receptor associated factor 2 Homo sapiens
2 TRAF3 knockdown, ectopic TRAF2, or BCL-XL expression significantly diminished birinapant/bortezomib toxicity. birinapant TNF receptor associated factor 2 Homo sapiens